This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

53/100

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Mild cognitive impairment

Topic: Brain proteins, microglia and lab models

Plain-language summary

In linear mixed models, vascular endothelial growth factor was significantly associated with incident DWI-positive lesions over 1 year. Intercellular adhesion molecule-1 was linked with lower CVR while platelet-derived growth factor-subunit B and Endothelin-1 were associated with higher CVR. Platelet-Selectin levels were associated with mild cognitive impairment at 1 year. Our results support the role of endothelial and pericyte dysfunction in SVD burden and progression and suggest that specific biomarkers relate to distinct SVD manifestations. HIGHLIGHTS: Small vessel disease (SVD) lacks specific or predictive biomarker signatures. Vascular endothelial growth factor levels were linked to incident lesions detected over 1 year. Circulating intercellular adhesion molecule-1 related to lower cerebrovascular reactivity. Platelet-selectin levels were associated with mild cognitive impairment longitudinally. These findings could help stratify patients at high-risk of rapid-progression SVD.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

García, D. J., Clancy, Ú., Arteaga, C., Hernández, M. d. C. V., Chappell, F. M., Jochems, A. C., et al. (2025). Blood biomarkers of vascular dysfunction in small vessel disease progression: Insights from a longitudinal neuroimaging study. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70152

Vancouver

García DJ, Clancy Ú, Arteaga C, Hernández MdCV, Chappell FM, Jochems AC, et al. Blood biomarkers of vascular dysfunction in small vessel disease progression: Insights from a longitudinal neuroimaging study. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70152. PMID: 40275856.

BibTeX

@article{garcia2025-40275856,
  author  = {García, Daniela Jaime and Clancy, Úna and Arteaga, Carmen and Hernández, Maria del Carmen Valdés and Chappell, Francesca M. and Jochems, Angela C.C. and Cheng, Yajun and Zhang, Junfang and others},
  title   = {{Blood biomarkers of vascular dysfunction in small vessel disease progression: Insights from a longitudinal neuroimaging study}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70152},
  pmid    = {40275856},
  url     = {https://doi.org/10.1002/alz.70152}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: this is a cross-sectional study. Everyone is measured once, so it cannot show which came first. Read it as a snapshot of how two things go together at one moment.
Size: the record lists 181 participants. Ask whether that is enough for the question, and who they were.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded moderate. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Moderate means the abstract mentions a cohort, case-control or longitudinal design. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

In linear mixed models, vascular endothelial growth factor was significantly associated with incident DWI-positive lesions over 1 year.
Intercellular adhesion molecule-1 was linked with lower CVR while platelet-derived growth factor-subunit B and Endothelin-1 were associated with higher CVR.
Platelet-Selectin levels were associated with mild cognitive impairment at 1 year.
Our results support the role of endothelial and pericyte dysfunction in SVD burden and progression and suggest that specific biomarkers relate to distinct SVD manifestations.
HIGHLIGHTS: Small vessel disease (SVD) lacks specific or predictive biomarker signatures.

Why it matters

In a longitudinal neuroimaging study, certain blood biomarkers of vascular dysfunction were linked to small vessel disease progression, and platelet-selectin levels were associated with mild cognitive impairment at one year. These findings could help stratify patients at high risk of rapid-progression small vessel disease, but they are not a treatment or cure.

Study details

Study designcross-sectional
Participants181
Evidence strengthModerate

How this study scored 53/100

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 51 of the 96 points we could judge it on, which is 53 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	4 / 12	A snapshot of people at one point in time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	181 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 14 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	4.7 citations a year over 3 year(s) since 2025
Impact for its field and year	3 / 6	Cited 7.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 2 other studies in this library
Still being cited	1 / 4	Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	1 / 3	University of Edinburgh: institution h-index 1,378 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 8 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40275856)
Free to read	2 / 2	Free to read
Points	51 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 51 of the 96 points we could judge it on is 53 out of 100.
Total	53 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Mild cognitive impairment from nearby years

Also tagged “small”

900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →